Bildkälla: Stockfoto

Xbrane Biopharma: US commercialization partner announced - Redeye

Redeye leave its comments on Xbrane following the announcement of a USD45m deal plus royalties for Xbrane's ranibizumab biosimilar on the US market.

Redeye leave its comments on Xbrane following the announcement of a USD45m deal plus royalties for Xbrane's ranibizumab biosimilar on the US market.
Börsvärldens nyhetsbrev
ANNONSER